Jian Jiang PhD.
event_seat Postdoctoral Fellow
Jian Jiang was born on October 18th, 1982, in Beijing, China. She commenced her undergraduate studies at Peking University in China and received her BSc in ‘Public Health and Preventive Medicine’ in 2007, where she developed a collagen-based scaffold for chondrocyte implantation. After graduation, she started working as a research associate at the Tissue Engineering Department within the JiShuiTan hospital for two years. During this period, she was involved in several projects and responsible for evaluating the safety, biocompatibility and mechanical stability of newly developed biomaterials.
In 2009, she continued her education with a Master’s program in Nutrition and Health at the Wageningen University and obtained her degree in September 2011. During the second year of this program, she completed two theses on “Identifying interacting proteins of angiopoietin-like protein 4” and “Molecular effects of quercetin on hepatic lipid metabolism”, respectively.
On the 15th of March 2012, she started working as a PhD student at the Toxicogenomics Department of Maastricht University. Under the supervision of Prof. Dr. Theo de Kok and Prof. Dr. Jos Kleinjans, she worked on the project entitled: ‘Mechanisms of Drug Induced Liver Injury: Toxicogenomics studies in different in vitro models’.
After her graduation, she started her Postdoc project aiming to solve the puzzle of asthma with the cutting-edge single-cell RNA-sequencing (scRNA-seq) technique in the Medical biology department at the University Medical Center Groningen. Through analyzing the scRNA-seq data, she identified a novel type of epithelial cells, named ionocytes, in human airways and visualized them in human lung tissue sections and designed experiments to understand the function of ionocytes based on the results of transcriptomic analyses.
Since March 2019 she has moved back to Maastricht and started her second postdoctoral project at the Department of Toxicogenomics at Maastricht University, which aims to identify critical transitions in the development of non-alcoholic fatty liver disease (NAFLD).